Clinical Trial Update: A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) [Phase 3]

View source ↗

Summary

Phase 3 results from the MAPP1 study evaluating MDMA-assisted psychotherapy for PTSD have been posted. The multi-site trial reports efficacy and safety findings…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttraumatic Stress Disorder

Drugs mentioned

• MDMA (3,4-methylenedioxymethamphetamine) (3,4-methylenedioxymethamphetamine)

Snippet

Sponsor: Lykos Therapeutics | Conditions: Posttraumatic Stress Disorder | Phase 3 | Status: COMPLETED | Results posted: 2021-09-16